DCF — STEWARD ST. ELIZABETHS MEDICAL CTR
Enterprise Value: $-56.7M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-56.7M
Enterprise Value
$-29.0M
PV of Cash Flows
$-27.7M
PV of Terminal Value
$-44.6M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $441.4M | $5.2M | 1.0% | $-13.5M | $-12.2M |
| Year 2 | $454.6M | $9.9M | 2.0% | $-9.3M | $-7.7M |
| Year 3 | $468.2M | $14.9M | 3.0% | $-5.7M | $-4.3M |
| Year 4 | $482.3M | $17.8M | 4.0% | $-4.1M | $-2.8M |
| Year 5 | $496.8M | $19.5M | 4.0% | $-3.3M | $-2.0M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-56.7M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$428.5M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.006854798154276705
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5